miRview Meso Test
The miRview® Meso Test, developed by Rosetta Genomics, can be used it to tell whether or not a patient has malignant pleural mesothelioma. It is extremely accurate because it measures microRNA in a tumor sample.
How Does MicroRNA Help Pathologists Diagnose Mesothelioma?
MicroRNA is a unique group of RNA genes that control gene expression during translation, which is the process during which the genetic information on an mRNA molecule is used to make proteins. MicroRNA is expressed differently in the various types of cancer. The microRNA is taken from a number of tissue and body fluid samples and is used to identify a microRNA signature that is specific to mesothelioma.
How is the Test Performed?
The tissue and body fluid samples used in the testing are formalin-fixed paraffin embedded. A sample that is formalin-fixed paraffin embedded is material that has been biopsied and then placed in paraffin wax to prevent it from decaying or degenerating so that it can be analyzed under a microscope.
It is extremely significant that the miRview Meso Test can use microRNA from formalin-fixed paraffin embedded samples. These samples do not require any refrigeration and can be maintained at room temperature and sent to the lab for evaluation by standard shipping.
After the microRNA is removed from the samples and evaluated, a set of tissue-specific microRNA biomarkers is used to differentiate mesothelioma from other types of cancer.
How are the Test Results Interpreted?
The test measures the level of three microRNA biomarkers. Two scores are calculated, which indicate the amount of the three specific microRNAs in the sample as measured by qualitative real-time PCR (qRT-PCR). Qualitative real-time polymerase chain reaction, or qRT-PCR, is a technique that is used to increase the intensity of and count how many there are of a specific DNA molecule.
The test scores are then compared to predefined normal values. When both scores are greater than zero, the test outcome is mesothelioma.
The test has been shown to be 100 percent specific for mesothelioma and 94 percent accuracy level for diagnosing all subtypes of the disease.